July 2020 – Mogrify adds Dr. Lorenz Mayr to Board of Directors and Scientific Advisory Board

PRESS RELEASE 7th July 2020

Mogrify adds Dr. Lorenz Mayr to Board of Directors and Scientific Advisory Board

Cambridge, UK, 7th July 2020: Mogrify Ltd (Mogrify®), a UK biotechnology company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, today announced the appointment of Lorenz Mayr, PhD, to the Board of Directors and the Scientific Advisory Board (SAB). Dr. Mayr will initially join the Board of Directors as an observer, providing valuable insights into the development and manufacture of ex vivo cell therapies and in vivo reprogramming therapies and advising on the Company’s therapeutic program selections, before assuming full board member status later this year.

Dr. Mayr has over 30 years’ experience in biopharma research, development and commercialization. He joins the Mogrify Board having most recently been Chief Technical Officer at GE Healthcare Life Sciences, where he was responsible for all global R&D activities, talent development and company growth strategy across all business areas including cell therapy manufacturing. His previous industry roles include Vice President & Global Head at AstraZeneca, where he oversaw the generation of biological reagents and assay development activities across all therapeutic areas, and Executive Director at Novartis Pharma AG. He is a Biochemistry lecturer at the Martin Luther University Halle-Wittenberg and has published over 60 papers in peer-reviewed journals. He obtained his PhD in Biochemistry and Biophysics at the University of Bayreuth. Dr. Mayr currently serves as an Entrepreneur in Residence at Syncona Ltd.

Darrin M. Disley, PhD, CEO, Mogrify, said: “We are excited to welcome Dr. Mayr to both the Board of Directors and the Scientific Advisory Board. His appointment further strengthens our senior team, which includes industry leaders in platform technologies, drug development and biotech company building. Lorenz’s expansive knowledge of pre-clinical R&D, clinical drug development and manufacture and his global biotech and pharma network will be invaluable in our mission to transform the development of lifesaving therapies in disease areas including hematology, immunology and ophthalmology.”

Lorenz Mayr, PhD, Board and SAB member, Mogrify, added: “Mogrify has developed an innovative direct cellular conversion technology that has a great potential for diseases with a high unmet clinical need. The Company is well-positioned to address shortcomings in the cell therapy space as well as pioneer in vivo reprogramming therapies, and I am pleased to be joining at such an exciting stage in its growth. I am looking forward to working with a team with proven world-class scientific and commercial expertise.”

For further information about Mogrify’s team, please visit: www.mogrify.co.uk/board-of-directors

Notes to Editors

Dr. Lorenz Mayr

Mogrify Board of Directors and SAB

For high-resolution and alternate images please contact Zyme Communications.

For further information please contact:

Mogrify
Darrin M Disley, PhD, OBE
Email: darrin@mogrify.com

Zyme Communications
Lorna Cuddon
Tel: +44 (0)7811 996 942
E-mail: lorna.cuddon@zymecommunications.com

Westwicke, an ICR Company (investor enquiries)
Stephanie Carrington
Tel: +1 (646) 277-1282
Email: stephanie.carrington@icrinc.com

About Mogrify www.mogrify.co.uk

Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.

The platform takes a systematic big-data approach to identify, from next-generation sequencing and gene-regulatory networks, the transcription factors (in vitro) or small molecules (in vivo), needed to convert a cell. By bypassing the stem cell-stage of cell transformation, Mogrify simultaneously addresses challenges associated with efficacy, safety and scalability.

Mogrify is deploying this platform to develop novel cell therapies addressing musculoskeletal, auto-immune, cancer immunotherapy, ocular and respiratory diseases as well as generating a broad IP position relating to cell conversions that exhibit safety, efficacy and scalable manufacturing profiles suitable for development as cell therapies.

Uniquely positioned to address a cell therapy market estimated to be $35 billion USD by 2023, Mogrify is commercializing its technology via IP licensing, product development, and drug development. Based in Cambridge, UK, the Company has raised over $20 million USD funding from Ahren Innovation Capital, Parkwalk, 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III.

Follow Mogrify on Twitter @Mogrify_UK and LinkedIn @Mogrify

 

Comments are closed.